Caeregen Therapeutics receives $1.4 million research grant for retinal disease candidate
Click Here to Manage Email Alerts
Key takeaways:
- Caeregen Therapeutics received a $1.4 million research grant.
- The funding will support the development of CTR-107 for the treatment of retinal-related vision loss.
Caeregen Therapeutics has been awarded a $1.4 million phase 2 Small Business Innovation Research grant for the development of CTR-107 for the treatment of retinal-related vision loss due to inherited and age-related diseases.
Caeregen will use the grant from the NIH and the National Eye Institute to build on prior research that “demonstrated production feasibility, safety/tolerability, modulation of target gene expression in vitro, and in vivo functional activity,” according to a press release.
Image: Adobe Stock
CTR-107 (Noregen), initially in development for the treatment of familial exudative vitreoretinopathy, is a synthetic targeted growth factor designed to regenerate retinal blood vessels and neurons by mimicking the properties of norrin when injected into the eye.
“The NIH grant will support the nonclinical development program of CTR-107 and accelerate our investigational new drug submission to begin clinical trials,” Walter Capone, CEO of Caeregen, said in the release.
Read more about
Click Here to Manage Email Alerts